1. Home
  2. SPRO vs FRD Comparison

SPRO vs FRD Comparison

Compare SPRO & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.34

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$17.62

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
FRD
Founded
2013
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
134.3M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
SPRO
FRD
Price
$2.34
$17.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
251.4K
24.7K
Earning Date
03-26-2026
02-09-2026
Dividend Yield
N/A
0.89%
EPS Growth
111.81
N/A
EPS
0.15
1.46
Revenue
$66,802,000.00
$121,157,278.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$12.34
Revenue Growth
39.24
55.82
52 Week Low
$0.51
$12.24
52 Week High
$3.09
$24.37

Technical Indicators

Market Signals
Indicator
SPRO
FRD
Relative Strength Index (RSI) 44.87 44.76
Support Level $2.31 $16.26
Resistance Level $2.44 $22.82
Average True Range (ATR) 0.12 0.90
MACD -0.02 0.11
Stochastic Oscillator 11.90 51.49

Price Performance

Historical Comparison
SPRO
FRD

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

Share on Social Networks: